Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants
ZNTL•Bookrunners
TD Cowen, Guggenheim Securities, and Oppenheimer are joint bookrunners.
Public offering launched
Zentalis Pharmaceuticals launched a proposed underwritten public offering of common stock.
Some investors can choose pre-funded warrants to buy common shares in lieu of stock.
Underwriter option and proposed use of proceeds
The underwriters hold a 30-day option to purchase up to 15% additional shares on the same terms.
Proceeds are earmarked for clinical trials, preclinical work, regulatory filings, manufacturing, companion diagnostic development, pre-commercial activities, capital spending, and working capital.
